Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04369703 · ClinicalTrials.gov registry record
Copeptin as a Biomarker for Central Diabetes Insipidus Development Following Pituitary Surgery
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 199
- Enrollment target
NCT04369703: Completed study, sponsored by Mayo Clinic.
NCT04369703 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 199 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04369703 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 199 participants
- Enrollment target
Study Summary
1. Access the optimal cut point value of copeptin which predicts development of central diabetes insipidus postoperatively with highest accuracy. 2. Access the optimal cut point value of copeptin which predicts the lack of central diabetes insipidus postoperatively with highest accuracy 3. Access the relative change in copeptin values between baseline and post-surgery as a predictor for diabetes insipidus development.
Primary Outcome
Using the measured lab value, we will access the optimal cut point value of copeptin which predicts development of central diabetes insipidus postoperatively with highest accuracy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2020-01-28 |
| Est. Completion | 2022-04-29 |
What the finished NCT04369703 record still lists
NCT04369703 is an observational study that tracks outcomes without assigning an intervention. The registered 199 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04369703 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04369703 about?
NCT04369703 is a clinical study titled "Copeptin as a Biomarker for Central Diabetes Insipidus Development Following Pituitary Surgery". 1. Access the optimal cut point value of copeptin which predicts development of central diabetes insipidus postoperatively with highest accuracy. 2. Access the optimal cut point value of copeptin which predicts the lack of central diabetes insipidus postoperatively with highest accuracy 3. Access th...
What is the current status of trial NCT04369703?
This trial is currently completed. The enrollment target is 199 participants. The study started on 2020-01-28. Estimated completion is 2022-04-29.
Who is sponsoring clinical trial NCT04369703?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04312126 · 199 participants
The Beneficial Effects of Naps on Motor Learning
- NCT04951622 · 199 participants · Phase 3
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- NCT06474533 · 199 participants
Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI